Hepatitis A Author: Catherine M. Dentinger, FNP, MS; Brian J. McMahon, MD, MACP
Editorial changes - 2009-11-04
Author information and module status
Prevention
Screening
Diagnosis
Consultation for Diagnosis
Hospitalization
Non-drug Therapy
Drug Therapy
Patient Education
Consultation for Management
Follow-up
Tables
Figures
References
Glossary
What's New
Patient Information
Additional Resources
Tools
References
1. 1Bell BP, Shapiro CN, Alter MJ, Moyer LA, Judson FN, Mottram K, et al. The diverse patterns of hepatitis A epidemiology in the United States-implications for vaccination strategies. J Infect Dis. 1998;178:1579-84. (PMID: 9815207)
2. 1Armstrong GL, Bell BP. Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization. Pediatrics. 2002;109:839-45. (PMID: 11986444)
3. 2Hadler SC, Webster HM, Erben JJ, Swanson JE, Maynard JE. Hepatitis A in day-care centers. A community-wide assessment. N Engl J Med. 1980;302:1222-7. (PMID: 6245363)
4. 2Staes CJ, Schlenker TL, Risk I, Cannon KG, Harris H, Pavia AT, et al. Sources of infection among persons with acute hepatitis A and no identified risk factors during a sustained community-wide outbreak. Pediatrics. 2000;106:E54. (PMID: 11015549)
5. 2McMahon BJ, Beller M, Williams J, Schloss M, Tanttila H, Bulkow L. A program to control an outbreak of hepatitis A in Alaska by using an inactivated hepatitis A vaccine. Arch Pediatr Adolesc Med. 1996;150:733-9. (PMID: 8673200)
6. 2Werzberger A, Mensch B, Nalin DR, Kuter BJ. Effectiveness of hepatitis A vaccine in a former frequently affected community: 9 years' followup after the Monroe field trial of VAQTA [Letter]. Vaccine. 2002;20:1699-701. (PMID: 11906754)
7. 2Averhoff F, Shapiro CN, Bell BP, Hyams I, Burd L, Deladisma A, et al. Control of hepatitis A through routine vaccination of children. JAMA. 2001;286:2968-73. (PMID: 11743837)
8. 2Hepatitis A vaccination programs in communities with high rates of hepatitis A. MMWR Morb Mortal Wkly Rep. 1997;46(26):600-3. (PMID: 9221328)
9. 2Craig AS, Watson B, Zink TK, Davis JP, Yu C, Schaffner W. Hepatitis A outbreak activity in the United States: responding to a vaccine-preventable disease. Am J Med Sci. 2007;334:180-3. (PMID: 17873531)
10. 1Wasley A, Samandari T, Bell BP. Incidence of hepatitis A in the United States in the era of vaccination. JAMA. 2005;294:194-201. (PMID: 16014593)
11. 2Zhou F, Shefer A, Weinbaum C, McCauley M, Kong Y. Impact of hepatitis A vaccination on health care utilization in the United States, 1996-2004. Vaccine. 2007;25:3581-7. (PMID: 17306908)
12. 2Van Herck K, Van Damme P. Inactivated hepatitis A vaccine-induced antibodies: follow-up and estimates of long-term persistence. J Med Virol. 2001;63:1-7. (PMID: 11130881)
13. 2Van Damme P, Leroux-Roels G, Law B, Diaz-Mitoma F, Desombere I, Collard F, et al. Long-term persistence of antibodies induced by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J Med Virol. 2001;65:6-13.(PMID: 11505437)
14. 2Van Herck K, Van Damme P, Lievens M, Stoffel M. Hepatitis A vaccine: indirect evidence of immune memory 12 years after the primary course. J Med Virol. 2004;72:194-6.(PMID: 14695659)
15. 3Van Damme P, Banatvala J, Fay O, Iwarson S, McMahon B, Van Herck K, et al. Hepatitis A booster vaccination: is there a need? Lancet. 2003;362:1065-71.(PMID: 14522539)
16. 2Rendi-Wagner P, Korinek M, Winkler B, Kundi M, Kollaritsch H, Wiedermann U. Persistence of seroprotection 10 years after primary hepatitis A vaccination in an unselected study population. Vaccine. 2007;25:927-31. (PMID: 17005304)
17. 2Williams JL, Bruden DA, Cagle HH, McMahon BJ, Negus SE, Christensen CJ, et al. Hepatitis A vaccine: immunogenicity following administration of a delayed immunization schedule in infants, children and adults. Vaccine. 2003;21:3208-11.(PMID: 12804849)
18. 1Letson GW, Shapiro CN, Kuehn D, Gardea C, Welty TK, Krause DS, et al. Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr. 2004;144:327-32. (PMID: 15001936)
19. 2Fiore AE, Shapiro CN, Sabin K, Labonte K, Darling K, Culver D, et al. Hepatitis A vaccination of infants: effect of maternal antibody status on antibody persistence and response to a booster dose. Pediatr Infect Dis J. 2003;22:354-9. (PMID: 12690277)
20. 2Bell BP, Negus S, Fiore AE, Plotnik J, Dhotre KB, Williams J, et al. Immunogenicity of an inactivated hepatitis A vaccine in infants and young children. Pediatr Infect Dis J. 2007;26:116-22. (PMID: 17259872)
21. 2Nolan T, Bernstein H, Blatter MM, Bromberg K, Guerra F, Kennedy W, et al. Immunogenicity and safety of an inactivated hepatitis A vaccine administered concomitantly with diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines to children less than 2 years of age. Pediatrics. 2006;118:e602-9. (PMID: 16950952)
22. 2Guerra FA, Gress J, Werzberger A, Reisinger K, Walter E, Lakkis H, et al; Pediatric Study Group for VAQTA. Safety, tolerability and immunogenicity of VAQTA given concomitantly versus nonconcomitantly with other pediatric vaccines in healthy 12-month-old children. Pediatr Infect Dis J. 2006;25:912-9. (PMID: 17006287)
23. 2Vogt TM, Wise ME, Bell BP, Finelli L. Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. J Infect Dis. 2008;197:1282-8. (PMID: 18422440)
24. 2Roush SW, Murphy TV; Vaccine-Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA. 2007;298:2155-63. (PMID: 18000199)
25. 3Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:1-23. (PMID: 16708058)
26. 2Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2007;56:1080-4. (PMID: 17947967)
27. 3Notice to readers: FDA approval of VAQTA® (hepatitis A vaccine, inactivated) for children aged >=1 year. MMWR Morb Mortal Wkly Rep. 2005;54:1026. [Full Text]
28. 2Rimland D, Guest JL. Response to hepatitis A vaccine in HIV patients in the HAART era. AIDS. 2005;19:1702-4. (PMID: 16184045)
29. 2Weissman S, Feucht C, Moore BA. Response to hepatitis A vaccine in HIV-positive patients. J Viral Hepat. 2006;13:81-6. (PMID: 16436125)
30. 2Overton ET, Nurutdinova D, Sungkanuparph S, Seyfried W, Groger RK, Powderly WG. Predictors of immunity after hepatitis A vaccination in HIV-infected persons. J Viral Hepat. 2007;14:189-93. (PMID: 17305885)
31. 2Launay O, Grabar S, Gordien E, Desaint C, Jegou D, Abad S, et al. Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study. J Acquir Immune Defic Syndr. 2008;49:272-5. (PMID: 18845961)
32. 2Schattner A. Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine. 2005;23:3876-86. (PMID: 15917108)
33. 2Ferreira CT, da Silveira TR, Vieira SM, Taniguchi A, Pereira-Lima J. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. J Pediatr Gastroenterol Nutr. 2003;37:258-61. (PMID: 12960646)
34. 2Diaz-Mitoma F, Law B, Subramanya A, Hoet B. Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents. Vaccine. 2008;26:1759-63. (PMID: 18336963)
35. 2Hammitt LL, Bulkow L, Hennessy TW, Zanis C, Snowball M, Williams JL, et al. Persistence of antibody to hepatitis A virus 10 years after vaccination among children and adults. J Infect Dis. 2008;198:1776-82. (PMID: 18976095)
36. 2Steffen R, Kane MA, Shapiro CN, Billo N, Schoellhorn KJ, van Damme P. Epidemiology and prevention of hepatitis A in travelers. JAMA. 1994;272:885-9. (PMID: 8078167)
37. 2Steffen R, Rickenbach M, Wilhelm U, Helminger A, Schär M. Health problems after travel to developing countries. J Infect Dis. 1987;156:84-91. (PMID: 3598228)
38. 3Koff RS. Preventing hepatitis A infections in travelers to endemic areas. Am J Trop Med Hyg. 1995;53:586-90. (PMID: 8561258)
39. 3Winokur PL, Stapleton JT. Immunoglobulin prophylaxis for hepatitis A. Clin Infect Dis. 1992;14:580-6. (PMID: 1554845)
40. 2Wasley A, Miller JT, Finelli L; Centers for Disease Control and Prevention (CDC). Surveillance for acute viral hepatitis--United States, 2005. MMWR Surveill Summ. 2007 Mar 16;56(3):1-24. (PMID: 17363893)
41. 2Mutsch M, Spicher VM, Gut C, Steffen R. Hepatitis A virus infections in travelers, 1988-2004. Clin Infect Dis. 2006;42:490-7. (PMID: 16421793)
42. 3Jong EC. United States epidemiology of hepatitis A: influenced by immigrants visiting friends and relatives in Mexico? Am J Med. 2005;118(Suppl 10A):50S-7S. (PMID: 16271542)
43. 3Connor BA. Hepatitis A vaccine in the last-minute traveler. Am J Med. 2005;118(Suppl 10A):58S-62S. (PMID: 16271543)
44. 2Kaltenböck A, Dubischar-Kastner K, Eder G, Jilg W, Klade C, Kollaritsch H, et al. Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: a single-blind, randomized, controlled phase 3 study. Vaccine. 2009;27:4483-9. (PMID: 19486955)
45. 2Centers for Disease Control and Prevention (CDC); Advisory Committee on Immunization Practices. Updated recommendations from the Advisory Committee on Immunization Practices (ACIP) for use of hepatitis A vaccine in close contacts of newly arriving international adoptees. MMWR Morb Mortal Wkly Rep. 2009;58:1006-7. (PMID: 19763077)
46. 2Corey L, Holmes KK. Sexual transmission of hepatitis A in homosexual men: incidence and mechanism. N Engl J Med. 1980;302:435-8. (PMID: 6243391)
47. 2Coutinho RA, Albrecht-van Lent P, Lelie N, Nagelkerke N, Kuipers H, Rijsdijk T. Prevalence and incidence of hepatitis A among male homosexuals. Br Med J (Clin Res Ed). 1983;287:1743-5. (PMID: 6416573)
48. 2Katz MH, Hsu L, Wong E, Liska S, Anderson L, Janssen RS. Seroprevalence of and risk factors for hepatitis A infection among young homosexual and bisexual men. J Infect Dis. 1997;175:1225-9. (PMID: 9129091)
49. 2Christenson B, Broström C, Böttiger M, Hermanson J, Weiland O, Ryd G, et al. An epidemic outbreak of hepatitis A among homosexual men in Stockholm. Hepatitis A, a special hazard for the male homosexual subpopulation in Sweden. Am J Epidemiol. 1982;116:599-607. (PMID: 7137147)
50. 2Hepatitis A among homosexual men—United States, Canada, and Australia. MMWR Morb Mortal Wkly Rep. 1992;41(9):155, 161-4. (PMID: 1741008)
51. 2Stokes ML, Ferson MJ, Young LC. Outbreak of hepatitis A among homosexual men in Sydney. Am J Public Health. 1997;87:2039-41. (PMID: 9431300)
52. 2Hepatitis A vaccination of men who have sex with men—Atlanta, Georgia, 1996-1997. MMWR Morb Mortal Wkly Rep. 1998;47(34):708-11. (PMID: 9746398)
53. 2Henning KJ, Bell E, Braun J, Barker ND. A community-wide outbreak of hepatitis A: risk factors for infection among homosexual and bisexual men. Am J Med. 1995;99(2):132-6. (PMID: 7625417)
54. 3Cotter SM, Sansom S, Long T, Koch E, Kellerman S, Smith F, et al. Outbreak of hepatitis A among men who have sex with men: implications for hepatitis A vaccination strategies. J Infect Dis. 2003;187:1235-40. (PMID: 12696002)
55. 2Hutin YJ, Sabin KM, Hutwagner LC, Schaben L, Shipp GM, Lord DM, et al. Multiple modes of hepatitis A virus transmission among methamphetamine users. Am J Epidemiol. 2000;152:186-92. (PMID: 10909956)
56. 2Schade CP, Komorwska D. Continuing outbreak of hepatitis A linked with intravenous drug abuse in Multnomah County. Public Health Rep. 1988;103:452-9. (PMID: 3140269)
57. 2Hepatitis A among drug abusers. MMWR Morb Mortal Wkly Rep. 1988;37(19):297-300, 305. (PMID: 3130560)
58. 2Harkess J, Gildon B, Istre GR. Outbreaks of hepatitis A among illicit drug users, Oklahoma, 1984-87. Am J Public Health. 1989;79:463-6. (PMID: 2929804)
59. 2Grinde B, Stene-Johansen K, Sharma B, Hoel T, Jensenius M, Skaug K. Characterisation of an epidemic of hepatitis A virus involving intravenous drug abusers—infection by needle sharing? J Med Virol. 1997;53:69-75. (PMID: 9298735)
60. 2Shaw DD, Whiteman DC, Merritt AD, el-Saadi DM, Stafford RJ, Heel K, et al. Hepatitis A outbreaks among illicit drug users and their contacts in Queensland, 1997. Med J Aust. 1999;170:584-7. (PMID: 10416427)
61. 2Stene-Johansen K, Skaug K, Blystad H, Grinde B. A unique hepatitis A virus strain caused an epidemic in Norway associated with intravenous drug abuse. The Hepatitis A Study Group. Scand J Infect Dis. 1998;30:35-8. (PMID: 9670356)
62. 2Villano SA, Nelson KE, Vlahov D, Purcell RH, Saah AJ, Thomas DL. Hepatitis A among homosexual men and injection drug users: more evidence for vaccination. Clin Infect Dis. 1997;25:726-8. (PMID: 9314468)
63. 2Mannucci PM, Gdovin S, Gringeri A, Colombo M, Mele A, Schinaia N, et al. Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med. 1994;120:1-7. (PMID: 7504424)
64. 2Robertson BH, Alter MJ, Bell BP, Evatt B, McCaustland KA, Shapiro CN, et al. Hepatitis A virus sequence detected in clotting factor concentrates associated with disease transmission. Biologicals. 1998;26:95-9. (PMID: 9811512)
65. 2Soucie JM, Robertson BH, Bell BP, McCaustland KA, Evatt BL. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion. 1998;38:573-9. (PMID: 9661691)
66. 2Mah MW, Royce RA, Rathouz PJ, Wang JG, White GC 2nd, Janco RL, et al. Prevalence of hepatitis A antibodies in hemophiliacs: preliminary results from the Southeastern Delta Hepatitis Study. Vox Sang. 1994;67 Suppl 1:21-2; discussion 23. (PMID: 8091730)
67. 2Hinthorn DR, Foster MT Jr, Bruce HL, Aach RD. An outbreak of chimpanzee associated hepatitis. J Occup Med. 1974;16:388-91. (PMID: 4836166)
68. 2Dienstag JL, Davenport FM, McCollum RW, Hennessy AV, Klatskin G, Purcell RH. Nonhuman primate-associated viral hepatitis type A. Serologic evidence of hepatitis A virus infection. JAMA. 1976;236:462-4. (PMID: 180303)
69. 1Kemper CA, Haubrich R, Frank I, Dubin G, Buscarino C, McCutchan JA, et al. Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients: a double-blind, randomized, placebo-controlled trial. J Infect Dis. 2003;187:1327-31. (PMID: 12696015)
70. 2Chen H, Cantrell CR. Prevalence and factors associated with self-reported vaccination rates among US adults at high risk of vaccine-preventable hepatitis. Curr Med Res Opin. 2006;22:2489-96. (PMID: 17257463)
71. 3Baral S, Sherman SG, Millson P, Beyrer C. Vaccine immunogenicity in injecting drug users: a systematic review. Lancet Infect Dis. 2007;7:667-74. (PMID: 17897609)
72. 2Vento S, Garofano T, Renzini C, Cainelli F, Casali F, Ghironzi G, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med. 1998;338:286-90. (PMID: 9445408)
73. 3Keeffe EB. Is hepatitis A more severe in patients with chronic hepatitis B and other chronic liver diseases? Am J Gastroenterol. 1995;90:201-5. (PMID: 7847285)
74. 2Keeffe EB, Iwarson S, McMahon BJ, Lindsay KL, Koff RS, Manns M, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology. 1998;27:881-6. (PMID: 9500723)
75. 2Majda-Stanislawska E, Bednarek M, Kuydowicz J. Immunogenicity of inactivated hepatitis A vaccine in children with chronic liver disease. Pediatr Infect Dis J. 2004;23:571-4. (PMID: 15194843)
76. 1Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, et al. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med. 2007;357:1685-94. (PMID: 17947390)
77. 2Krugman S. Effect of human immune serum globulin on infectivity of hepatitis A virus. J Infect Dis. 1976;134:70-4. (PMID: 181498)
78. 2Stokes J, Neefe JR. The prevention and attenuation of infectious hepatitis by gamma globulin: preliminary note. JAMA. 1945;127:144-5.
79. 2Kluge T. Gamma-globulin in the prevention of viral hepatitis: a study on the effect of medium-size doses. Acta Med Scand. 1963;174:469-77.
80. 2Sonder GJ, van Steenbergen JE, Bovee LP, Peerbooms PG, Coutinho RA, van den Hoek A. Hepatitis A virus immunity and seroconversion among contacts of acute hepatitis A patients in Amsterdam, 1996-2000: an evaluation of current prevention policy. Am J Public Health. 2004;94:1620-6. (PMID: 15333325)
81. 2Bianco E, De Masi S, Mele A, Jefferson T. Effectiveness of immune globulins in preventing infectious hepatitis and hepatitis A: a systematic review. Dig Liver Dis. 2004;36:834-42. (PMID: 15646432)
82. 3Sagliocca L, Amoroso P, Stroffolini T, Adamo B, Tosti ME, Lettieri G, et al. Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial. Lancet. 1999;353:1136-9. (PMID: 10209977)
83. 2Hepatitis Surveillance Report No. 60. Atlanta, GA: Centers for Disease Control and Prevention; September 2005.
84. 2Lednar WM, Lemon SM, Kirkpatrick JW, Redfield RR, Fields ML, Kelley PW. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol. 1985;122:226-33. (PMID: 3860002)
85. 1Tong MJ, el-Farra NS, Grew MI. Clinical manifestations of hepatitis A: recent experience in a community teaching hospital. J Infect Dis. 1995;171 Suppl 1:S15-8. (PMID: 7876641)
86. 3Hadler SC, McFarland L. Hepatitis in day care centers: epidemiology and prevention. Rev Infect Dis. 1986;8:548-57. (PMID: 3018889)
87. 3Tabor E. Guillain-Barré syndrome and other neurologic syndromes in hepatitis A, B, and non-A, non-B. J Med Virol. 1987;21:207-16. (PMID: 2881973)
88. 3Lemon SM. Type A viral hepatitis. New developments in an old disease. N Engl J Med. 1985;313:1059-67. (PMID: 2413356)
89. 2Liaw YF, Yang CY, Chu CM, Huang MJ. Appearance and persistence of hepatitis A IgM antibody in acute clinical hepatitis A observed in an outbreak. Infection. 1986;14:156-8. (PMID: 3759243)
90. 2Decker RH, Kosakowski SM, Vanderbilt AS, Ling CM, Chairez R, Overby LR. Diagnosis of acute hepatitis A by HAVAB-M, a direct radioimmunoassay for IgM anti-HAV. Am J Clin Pathol. 1981;76:140-7. (PMID: 6267929)
91. 3Hoofnagle JH, Di Bisceglie AM. Serologic diagnosis of acute and chronic viral hepatitis. Semin Liver Dis. 1991;11:73-83. (PMID: 1909458)
92. 2Bradley DW, Maynard JE, Hindman SH, Hornbeck CL, Fields HA, McCaustland KA, et al. Serodiagnosis of viral hepatitis A: detection of acute-phase immunoglobulin M anti-hepatitis A virus by radioimmunoassay. J Clin Microbiol. 1977;5:521-30. (PMID: 194916)
93. 2de Paula VS, Villar LM, Morais LM, Lewis-Ximenez LL, Niel C, Gaspar AM. Detection of hepatitis A virus RNA in serum during the window period of infection. J Clin Virol. 2004;29:254-9. (PMID: 15018853)
94. 3Glikson M, Galun E, Oren R, Tur-Kaspa R, Shouval D. Relapsing hepatitis A. Review of 14 cases and literature survey. Medicine (Baltimore). 1992;71:14-23. (PMID: 1312659)
95. 2Positive test results for acute hepatitis A virus infection among persons with no recent history of acute hepatitis—United States, 2002-2004. MMWR Morb Mortal Wkly Rep. 2005;54:453-6. (PMID: 15889006)
96. 2Taylor RM, Davern T, Munoz S, Han SH, McGuire B, Larson AM, et al. Fulminant hepatitis A virus infection in the United States: incidence, prognosis, and outcomes. Hepatology. 2006;44:1589-97. (PMID: 17133489)
97. 3McMahon BJ, Shapiro CN, Robertson BH. Hepatitis A. In: Haubrich WS, Schaffner F, Berk JE, eds. Gastroenterology. 5th ed. Philadelphia, PA: W. B. Saunders Company; 1995:2044-61.
98. 2Humphrey MJ, Hansen RC, Bradley DW, Nagle RB, Stillman AE. Severe clotting abnormalities and transient hepatic fibrosis in acute anicteric hepatitis A. J Pediatr. 1979;95:987-9. (PMID: 228018)
99. 2Hagler L, Pastore RA, Bergin JJ, Wrensch MR. Aplastic anemia following viral hepatitis: report of two fatal cases and literature review. Medicine (Baltimore). 1975;54:139-64. (PMID: 1117835)
100. 2Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. Am J Public Health. 1996;86:655-61. (PMID: 8629715)
101. 2Goldstein ST, Alter MJ, Williams IT, Moyer LA, Judson FN, Mottram K, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis. 2002;185:713-9. (PMID: 11920288)
102. 2Crabb DW, Lumeng L. Alcoholic liver disease. In: Haubrich WS, Schaffner F, Berk JE, eds. Gastroenterology. 5th ed. Philadelphia, PA: W. B. Saunders Company; 1995:2215-45.
103. 2Vento S, Garofano T, Di Perri G, Dolci L, Concia E, Bassetti D. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet. 1991;337:1183-7. (PMID: 1673738)
104. 3Rahaman SM, Chira P, Koff RS. Idiopathic autoimmune chronic hepatitis triggered by hepatitis A. Am J Gastroenterol. 1994;89:106-8. (PMID: 8273775)
105. 3Hoofnagle JH, Carithers RL Jr, Shapiro C, Ascher N. Fulminant hepatic failure: summary of a workshop. Hepatology. 1995;21:240-52. (PMID: 7806160)
106. 2Zhang RL, Zeng JS, Zhang HZ. Survey of 34 pregnant women with hepatitis A and their neonates. Chin Med J (Engl). 1990;103:552-5. (PMID: 1698588)
107. 1Elinav E, Ben-Dov IZ, Shapira Y, Daudi N, Adler R, Shouval D, et al. Acute hepatitis A infection in pregnancy is associated with high rates of gestational complications and preterm labor. Gastroenterology. 2006;130:1129-34. (PMID: 16618407)
108. 2Willner IR, Uhl MD, Howard SC, Williams EQ, Riely CA, Waters B. Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med. 1998;128:111-4. (PMID: 9441570)
109. 2Carl M, Francis DP, Maynard JE. Food-borne hepatitis A: recommendations for control. J Infect Dis. 1983;148:1133-5. (PMID: 6655295)
110. 2Yaghi C, Honein K, Boujaoude J, Slim R, Moucari R, Sayegh R. Influence of acetaminophen at therapeutic doses on surrogate markers of severity of acute viral hepatitis. Gastroenterol Clin Biol. 2006;30:763-8. (PMID: 16801900)
111. 3Whiting PW, Clouston A, Kerlin P. Black cohosh and other herbal remedies associated with acute hepatitis. Med J Aust. 2002;177:440-3. (PMID: 12381254)
112. 3Hepatic toxicity possibly associated with kava-containing products—United States, Germany, and Switzerland, 1999-2002. MMWR Morb Mortal Wkly Rep. 2002;51:1065-7. (PMID: 12500906)
113. 2Gordon SC, Reddy KR, Schiff L, Schiff ER. Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med. 1984;101:635-7. (PMID: 6486595)
114. 2Sagnelli E, Coppola N, Marrocco C, Onofrio M, Scarano F, Marotta A, et al. HAV replication in acute hepatitis with typical and atypical clinical course. J Med Virol. 2003;71:1-6. (PMID: 12858402)
115. 2Havens WP. Immunity in experimentally induced infectious hepatitis. J Exp Med. 1946;84:403.
FAQs
Brian J. McMahon, MD, MACP has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations. Catherine M. Dentinger, FNP, MS has no financial relationships with pharmaceutical companies, biomedical device manufacturers, or health-care related organizations.
Steven E. Weinberger, MD, FACP, Acting Editor, PIER, has stock holdings in Glaxosmithkline and Abbott.

The information included herein should never be used as a substitute for clinical judgment and does not represent an official position of ACP. Because all PIER modules are updated regularly, printed web pages or PDFs may rapidly become obsolete. Therefore, PIER users should compare the date of the last update on the website with any printout to ensure that the information being referred to is the most current available.
PIER is copyrighted (c) 2009 by the American College of Physicians,
190 N. Independence Mall West, Philadelphia, PA 19106-1572, USA.